Compare Crispr Therapeutics AG (CRSP) vs JetBlue Airways Corporation (JBLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs JetBlue Airways Corporation — how do they compare? Crispr Therapeutics AG trades at $51.49 (market cap $4.97B), while JetBlue Airways Corporation trades at $5.33 (market cap $1.99B). The key difference: Crispr Therapeutics AG is far larger — about 2.5× JetBlue Airways Corporation's market cap, and JetBlue Airways Corporation is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | JBLU | |
|---|---|---|
Market Cap | $4.97B | $1.99B |
Sector | Health | Industrials |
52-Week High | $76.78 | $6.46 |
52-Week Low | $44.34 | $4.03 |
Enterprise Value | $3.32B | $9.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
JetBlue (JBLU) trades at $5.60, down 2.78% on the day, with a neutral technical signal and mixed fundamental picture. The airline reported negative net income margins of -7.78% and has missed earnings expectations in recent quarters, though it beat in Q3 2025. Recent news highlights expansion at Fort Lauderdale airport and sector-wide pressure from fuel costs. Analyst consensus is mixed with 61% hold ratings and a $5.12 price target slightly below current levels.
The outlook remains challenging with persistent losses and high debt levels, though strategic expansions and potential fuel cost relief offer some upside. Key risks include competitive pressures, volatile fuel prices, and execution of turnaround efforts. The stock presents a speculative opportunity for investors betting on operational improvements amid sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →
